Background Maintaining stable levels of anticoagulation using warfarin therapy is challenging. Few studies have examined the stability of the international normalized ratio (INR) in patients with nonvalvular atrial fibrillation (NVAF) who have had C6 months' exposure to warfarin anticoagulation for stroke prevention. Objective Our objective was to describe INR control in NVAF patients who had been receiving warfarin for at least 6 months. Methods Using retrospective patient data from the CoagClinic TM database, we analyzed data from NVAF patients treated with warfarin to assess the quality of 
Introduction
Atrial fibrillation (AF) is a common and clinically significant cardiac arrhythmia. It is estimated that 2.3 million Americans have AF [1, 2] , and its prevalence is expected to & Winnie W. Nelson wnelson@its.jnj.com increase 2.5-fold by 2050 [1] . AF is an important concern to the healthcare system, because it increases the risk of stroke up to fivefold [3] , and AF-related stroke is typically more severe and carries a higher mortality rate than stroke not associated with AF [4] . Increased time in therapeutic range (TTR) correlates with improved patient outcomes and lower costs [5] . Longterm anticoagulants are recommended by guidelines for the prevention of stroke among high-risk AF patients [6] , and warfarin has been widely used for stroke prevention in such patients with nonvalvular AF (NVAF). A 2007 meta-analysis of 13 randomized clinical trials showed that doseadjusted warfarin reduced the relative risk of stroke by 64 % compared with placebo [7] . Achieving stable international normalized ratio (INR) values is critical but can be challenging. In a recent study that examined INR patterns in more than 15,000 patients with NVAF newly initiated on warfarin, 25 % of patients failed to achieve INR stabilization during their treatment, and most of these patients ultimately discontinued warfarin therapy [8] .
While several studies have explored the difficulties of achieving target INR values among patients who are new to warfarin therapy, few studies have focused on the experience of patients who have overcome the initial hurdles of INR control and have used warfarin for more than 6 months. Furthermore, few studies have examined determinants of INR control. Of those that have, most have focused only on the occurrence of sub-therapeutic INR values (i.e., INR \2.0) and have not examined the occurrence and impact of supra-therapeutic INR values (i.e., INR [3.0) .
Therefore, the objective of the current study was to describe INR control in NVAF patients who had been receiving warfarin for at least 6 months. We examined the occurrence of both sub-therapeutic and supra-therapeutic INR values in this population and the management patterns in response to readings of INR C4.0. In addition, we assessed predictors of poor INR control among 'experienced' warfarin patients.
Methods

Data and Study Design
This was a retrospective analysis of a database of patientlevel anticoagulation management records collected between 2006 and 2010 by CoagClinic TM , a decision-support software system. CoagClinic TM software is used by a large number of institutions, mostly hospital based, in 49 states in the USA. As of December 2010, the database contained records of approximately 400,000 patients and represented the largest database of patients receiving anticoagulation therapy. The database contains demographic information, medical indication for warfarin, INR goal, INR range, medical history, detailed encounter data from each patient visit (such as date of service), and INR values. The medical history data were recorded in text and were recoded into analyzable data by the research team. The CHADS 2 (congestive heart failure, hypertension, age C75 years, diabetes mellitus, stroke/transient ischemic attack) and CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age C75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) scores were calculated based on the recoded medical history data. Because the database was intended for clinical care documentation, medical history was recorded as free text. The text data were recoded into International Classification of Diseases 9th Revision, Clinical Modification codes by the research team in order to enable analytics programming.
Eligibility Criteria
Adults with a diagnosis of NVAF with at least three INR values and available medical history data were identified. Adults were defined as patients aged 18 years or older as of their warfarin initiation date (1 January 2006 to 31 December 2010). Patients were tracked from their first INR measurement until the end of data availability (31 December 2010) or until the occurrence of a 90-day visit gap. Patients were included in the analysis if they had at least 6 months of observable follow-up time. The warfarin initiation date was confirmed for each patient by ensuring that the year of warfarin initiation matched that of the patient's first visit date. Patients included had been using warfarin for at least 6 months and were thus considered warfarinexperienced based on the Veterans Affairs Study to Improve Anticoagulation [9] . The current analysis analyzed all INR data between the end of the first 6 months and the end of the observation period.
Measurement of International Normalized Ratio (INR) Control
The TTR was calculated for INR as within the recommended therapeutic range of 2.0-3.0 using the Rosendaal method [10] 
Statistical Methods: Descriptive Statistics
Demographic characteristics reported included age and sex, and health characteristics included history of congestive heart failure, diabetes, hypertension, stroke, and vascular disease, as well as the CHADS 2 and CHA 2 DS 2 -VASc risk stratification schemes [12, 13] . These patient characteristics were baseline variables and were collected at the time of warfarin initiation. The study report was written in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [14] .
Results
Descriptive Statistics
The study sample represented 9433 patients who met the inclusion criteria and had been using warfarin for [6 months ( Table 1 ). The mean age was 72.6 ± 10.4 years, and 46 % of the sample was female. Of the patients, 12 % had a history of congestive heart failure, 18 % had diabetes, 51 % had hypertension, 4 % had stroke, and 12 % had vascular disease.
INR Patterns
INR data starting at 6 months following warfarin initiation were examined. Mean follow-up time was 544 ± 397 days, and patients had an average of 1.6 ± 0.7 measurements per 30 days (Table 2 ). More than 90 % of patients had at least one INR value below the therapeutic range (\2.0), and 82 % of patients were exposed to at least one INR [3.0. Moreover, 34 % of patients had at least one reading between 4.0 and 5.0; 12 % had at least one reading between 5.0 and 6.0; and 8 % had at least one reading of INR C6.0 (Fig. 1) . The only statistically significant coefficients were geography and sex ( Coefficients for the other demographic and health characteristics were not statistically significant.
Discussion
Studies of newer oral anticoagulants have demonstrated that warfarin-experienced patients have unique characteristics and experience different outcomes than do newly initiated patients [15] . In addition, a recent publication by Schneeweiss et al. [16] cautioned on the risk of confounding bias when conducting real-world analyses combining data from new and experienced users of anticoagulants. Because the majority of real-world studies of INR stability in patients with AF focus on newly This study examined INR control in warfarin-experienced patients with NVAF-those who had been using warfarin for at least 6 months at study entry. For the average In addition, a large portion of patients were exposed to INR [4.0; such high INR values indicate exposure to higher bleeding risk. We also observed that these patients consumed more healthcare resources, with an average of one additional follow-up visit in the following month, compared with the overall cohort. For these patients, it took approximately 3 weeks on average to establish an in-range INR reading. While our analysis revealed some predictors for poor INR control in general, we found that demographic and health characteristics were not helpful in predicting likelihood of exposure to supra-therapeutic INR values. Most likely, this is because a high INR reading may be induced by acute events such as worsening of comorbidities or changes in diet or other medication use.
Our results corroborate previous findings in the literature related to the difficulty of achieving INR control. Rose et al. [9] studied determinants of INR control separately among patients in the first 6 months and after 6 months of warfarin use. This analysis of experienced warfarin users included about 100,000 patients in the Veterans Health Administration system. The average TTR among this group was 61 %, which is very similar to the TTR of 67 % in the current study. This study used TTR as its dependent variable of interest and examined how a number of risk factors predict TTR. According to Rose et al. [9] , predictors of low TTR among these patients included female sex, a greater number of hospitalizations, use of more medications, alcohol abuse, cancer, dementia, non-alcohol substance abuse, and chronic liver disease. Our study focused on fewer risk factors while adding to the literature by examining patterns of INR in more detail, including a description of the occurrence of sub-therapeutic and supra-therapeutic INR values and the impact of very high INR values on anticoagulation management. Our findings were also similar to those of a metaanalysis conducted by Baker and colleagues [5] examining INR control in patients with AF managed in an anticoagulation clinic versus in a community setting. The mean TTR in patients managed in an anticoagulation clinic was 63 % compared with 51 % for patients managed in a community practice.
A study conducted in the Netherlands focused on health characteristics and INR patterns once patients had reached stability [17] . This study included patients receiving vitamin K antagonists (e.g., warfarin) at an anticoagulation clinic regardless of indication. INR stability was defined as four consecutive in-range INR values (in-range was defined as 2.0-3.5 for low-intensity treatment and 2.5-4.0 for highintensity treatment). Average time to stabilization was 12 weeks. At 4 weeks after stabilizing, 12 % of patients had a risk of sub-therapeutic INR values. This percentage of patients increased to 21 % after 8 weeks and 50 % after 40 weeks. While these investigators found that 50 % of patients were at risk of exposure to sub-therapeutic INR values 40 weeks following stabilization [17] , we found a much higher percentage: after 6 months of warfarin use, [90 % of patients had a sub-therapeutic INR during an average of 78 weeks of observation. This difference may be related to the definitions of in-range INR values: specifically, while we use a fixed therapeutic range, Rombouts et al. [17] used different ranges depending on whether a patient was deemed appropriate for low-or highintensity treatment.
Witt et al. [18] conducted a retrospective analysis of approximately 7500 patients to study determinants of INR stabilization, defined as an INR value within the therapeutic range continuously for a 6-month period. A total of 33 % of the sample achieved stabilization. Predictors of stabilization were older age ([70 years) and having no comorbid heart failure or diabetes. Consistent with Witts et al. [18] , we found that older age correlated with better INR control, as did not having comorbid congestive heart failure.
Limitations
This analyses has several limitations. The data were generalizable only to patients managed in anticoagulation clinics. INR patterns might differ in patients who are managed elsewhere. Observational data might contain inaccuracies because of errors in recording the information. The extended follow-up period might have minimized the impact of an occasional inaccurate INR reading. The analytic models used in our study included variables available in the data but could not adjust for unobserved patient characteristics such as diet, concomitant medication, and certain comorbidities. Therefore, residual confounding may exist. The available data allowed patients to be followed until they discontinued anticoagulation management clinic visits. The reasons for discontinuation were not part of the dataset, nor were clinical outcomes. Therefore, the current analysis was limited to describing INR patterns and their associations with certain patient characteristics, with no assumptions regarding patient disposition.
Conclusions
Our analysis examined INR control among patients who had at least 6 months of warfarin experience and found evidence of poor INR control even after this longer-term use. A significant portion of the patient cohort experienced an INR C4.0, with an associated increase in follow-up visits. Moreover, we found that, while certain patient characteristics were predictors of poor INR control, these characteristics could not predict who was at increased risk of high INR values, further emphasizing the unpredictability of warfarin therapy. More research is needed to determine the clinical and economic outcomes of thrombosis and bleeding events associated with exposure to outof-range INR values.
